An observational study in Sarcoma and Giant Cell Tumor of Bone, sponsored by University of Calgary. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by University of Calgary · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 242 under way, 4 of them phase 3. Sarcoma · United States.
Among the 958 studies in Sarcoma with a site in United States, this one is the 25th largest by planned enrollment of the 100 observational ones that give a count, is one of 44 that started in 2025, is one of 100 observational ones, reaches primary completion later than 208 of the 240 other live ones, and was the 928th registered.
1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 65–100
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Iovance Biotherapeutics, Inc. · Sites in United States
Ages 16–70
St. Jude Children's Research Hospital · Sites in United States
City of Hope Medical Center · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
958 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 393 · Phase 2 426 · Phase 3 42 · Phase 4 4
First in 1983; this study’s year is marked. 44 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 120 across 220 observational studies indexed under Sarcoma.
Median enrollment 35 across the 800 interventional studies, 101 across the 100 observational. Of the 652 that completed or were terminated, 245 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 958 have an industry lead sponsor. The 10 most frequent:
University of Calgary is the lead sponsor of 704 studies on the registry; 197 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.
University of Calgary has 3 studies filed under Sarcoma — fewer than ten, so there is no comparison to draw.
76 of the studies in Sarcoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01223248Phase 3Memorial Sloan Kettering Cancer CenterRandomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | 2027-10 |
| NCT02307630Memorial Sloan Kettering Cancer CenterPET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study | 2026-11 |
| NCT05099666Massachusetts General HospitalLurbinectedin + Doxorubicin In Leiomyosarcoma | 2026-12 |
| NCT03114527Fox Chase Cancer CenterPhase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | 2026-12 |
| NCT00582647Memorial Sloan Kettering Cancer CenterCollection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract | 2026-12 |
Add all 76 to your calendar (.ics) → With an account.
Among the 958 studies in Sarcoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcoma is a rare form of bone and soft tissue cancer, making up about 1% of all adult cancers. Management typically involves radiation therapy, chemotherapy, and surgical resection. Surgery is central to the treatment of bone and soft tissue sarcoma, yet post-surgical recovery is difficult to measure because of disease rarity, multiple different tumor types, and treatment variation. Therefore, the overall goal of the study is to use patient reported outcome measures and mobility data to define recovery trajectories in sarcoma patients undergoing surgery, and to evaluate a novel smartphone application (app) entailed Activation Health for collecting these data.
Participants will download the Activation Health app on their smartphone. A demographics survey and multiple patient reported outcome measures will be administered remotely through the Activation Health app. Surveys will be completed preoperatively and at 6 weeks, 12 weeks, 6 months 12 months, 16 months, 20 months, and 24 months postoperatively. Additionally, the app will passively track mobility metrics such as daily step count, stairs climbed, and gait parameters throughout the study period. At the end of study participation, an additional surveys will be administered assess participant phone use habits and app function.
Background \& Rationale:
Sarcoma is a rare form of bone and soft tissue cancer, making up about 1% of all adult cancers. Management typically involves radiation therapy, chemotherapy, and surgical resection, with or without limb reconstruction. The diagnosis, intensive treatment regimen, and surgery-induced deficits significantly impact patient quality of life and function.
Surgery is central to the treatment of bone and soft tissue sarcoma, yet postoperative recovery is difficult to measure because of disease rarity, heterogeneity, and treatment variation. Legacy instruments such as the Toronto Extremity Salvage Score (TESS) have ceiling effects, limited health-domain coverage, and response burden. The Patient-Reported Outcomes Measurement Information System (PROMIS) uses short surveys across multiple health domains that may better capture recovery. PROMIS was developed with oncology research considerations and has been validated in both orthopaedic and oncology populations. However, the significance of PROMIS in orthopaedic oncology is not well understood.
Assessing patient reported outcomes is limited by survey completion rates, particularly in the oncology patients who have multiple medical appointments and care teams. To address these challenges, our team has developed Activation Health, a smartphone application (app) tailored to musculoskeletal oncology. Unlike general fitness or commercial health applications, Activation Health remotely administers patient reported outcome measures (PROMs) and passively captures mobility metrics. The continuous data collection aligns real-world mobility with clinical recovery timelines, offering a more precise view of patient outcomes.
The overall aim of the study is to validate the PROMIS as an outcome measure in the sarcoma population, and to evaluate the Activation Health app for remote PROM administration and mobility data collection.
Hypothesis:
PROMIS and mobility metrics will provide a holistic and granular view of recovery trajectories, and the use of a novel smartphone application will improve patient engagement and data collection.
Specific Aims:
Methods:
Recruitment and Sample Size:
This is a prospective, multicentre longitudinal cohort study involving the University of Calgary, University of Toronto, Mayo Clinic Rochester and Mayo Clinic Arizona. All eligible patients will be seen by a musculoskeletal oncology surgeons at one of the participating sites. Adult patients (≥18 years) diagnosed with an operative bone or soft tissue sarcoma are eligible for inclusion. Tumors can be primary or recurrent, and can be located in the upper extremities, pelvis, or lower extremities. Participants must speak English to be included in the study. The investigators anticipate enrolling approximately 800 sarcoma patients based on current surgical volumes and patient capture rates for collecting quality of life and functional data.
Data Collection:
Clinical data will be collected by an approved member of the research team using the local electronic medical record and a standardized case repot form. Participants will download the Activation Health app on their smartphone. A demographics survey, TESS, and PROMIS physical function, upper extremity, pain interference, global health, and self efficacy surveys will be administered remotely through the Activation Health app and Qualtrics. Completion of these surveys will be prompted via push notifications preoperative and at 6 weeks, 12 weeks, 6 months 12 months, 16 months, 20 months, and 24 months postoperative. Mobility metrics will be passively collected by the app throughout study involvement. The mobility metrics of interest include but are not limited to step count, distance travelled, move time, flights of stairs climbed, walking steadiness, walking asymmetry, double support time, walking speed, and step length. Additionally, physiological parameters such as maximum oxygen consumption (VO2 max) will be collected from participants with a compatible smartwatch. At the end of study participation, an additional surveys will be administered assess participant phone use habits and app function.
To improve study accessibility, participants without a compatible smartphone or unwilling to use the Activation Health app can contribute survey data using Qualtrics. The secure Qualtrics survey links will be distributed via email or text message (patient preference) by an approved member of the study team at pre-specified data collection timepoints. In addition, participants may contribute their mobility data at the end of study involvement during an in-person visit. For apple device users, secure data transfer can be facilitated via the AirDrop feature and for Android users via Google Takeout.
Statistical Analysis:
Summary statistics will describe population demographic and clinical characteristics. Continuous data will be represented as means with standard deviation or medians with interquartile range, and categorical data as proportions. Individual-level socioeconomic status will be calculated using household income, education level, and occupation.
The sensitivity of the PROMIS physical function and upper extremity function domains will be independently compared to the TESS using effect size and standardized response means. These measures will allow for comparison of whether the T-scores scores changed by a small or large amount over time. Additionally, the aggregate score of all the PROMIS domains will be compared to TESS. Aggregate scores will be calculated by averaging the five domain-specific T-scores. MCIDs for PROMIS domains will be calculated using an anchor-based method with the Global Rating of Change. The sensitivity of PROMIS will be compared to TESS using correlation coefficients, Bland-Altman plots, and linear regression models.
Mobility data will undergo principal component analysis to derive a composite index capturing the key features of interest. Ordinal logistic regression will be used to determine if mobility metrics collected form a smartphone are associated with patient-reported activity level, as assessed by a seven-point PGIC anchor question. Linear mixed-effects regression models will assess whether mobility changes are associated with changes in PROMIS and TESS scores.
The proportion of PROMIS and TESS questionnaires that are completed will be calculated. Logistic regression will be used to identify demographic factors that predict survey completion, with survey completion represented as a binary variable (yes or no).
The criteria were revised on the registry on Nov 2, 2026. See what changed
The investigators will enrol patients under the care of a musculoskeletal oncology surgeon at Foothills Medical Centre (Calgary, AB, Canada), Mount Sinai Hospital (Toronto, ON, Canada), Mayo Clinic Arizona (Phoenix, AZ, United States), and Mayo Clinic Minnesota (Rochester, MN, United States).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients treated with surgery for bone and soft tissue sarcoma, and giant cell tumor of bone
Procedure: Surgery
Any type of surgery performed to remove the primary tumor including resection, amputation, and bone stabilization.
Also known as: Operation, Procedure, Tumor resection, Amputation, Bone stabilization
Step count
Number of steps
Time frame: From enrolment to two years postoperative
Distance travelled
Kilometers
Time frame: From enrolment two years postoperative
Move time
Minutes
Time frame: From enrolment two years postoperative
Flights of stairs climbed
Number of flights climbed
Time frame: From enrolment to two years postoperative
Walking Steadiness
Percentage
Time frame: From enrolment two years postoperative
Walking asymmetry
Percentage
Time frame: From enrolment two years postoperative
Double Support Time
Percentage
Time frame: From enrolment two years postoperative
Walking Speed
Kilometers/hour
Time frame: From enrolment two years postoperative
Step Length
Centimeters
Time frame: From enrolment two years postoperative
Heart rate variability
Milliseconds. Measures the variation in time between each beat of your heart, with a higher score generally indicating better physical fitness.
Time frame: From enrolment to two years postoperative
PROMIS Physical Function
Scored using standardized T-scores with a mean of 50 and a standard deviation of 10. Scores above 50 indicate more of the measured trait, while scores below 50 indicate less.
Time frame: From enrolment to two years postoperative
PROMIS Upper Extremity Function
Scored using standardized T-scores with a mean of 50 and a standard deviation of 10. Scores above 50 indicate more of the measured trait, while scores below 50 indicate less.
Time frame: From enrolment to two years postoperative
PROMIS Pain Interference
Scored using standardized T-scores with a mean of 50 and a standard deviation of 10. Scores above 50 indicate more of the measured trait, while scores below 50 indicate less.
Time frame: From enrolment to two years postoperative
PROMIS Global Health
Scored using standardized T-scores with a mean of 50 and a standard deviation of 10. Scores above 50 indicate more of the measured trait, while scores below 50 indicate less.
Time frame: From enrolment to two years postoperative
PROMIS Self Efficacy
Scored using standardized T-scores with a mean of 50 and a standard deviation of 10. Scores above 50 indicate more of the measured trait, while scores below 50 indicate less.
Time frame: From enrolment to two years postoperative
Toronto Extremity Salvage Score Lower Extremity
Sum of patient responses for each question on a 5-point Likert scale, excluding "not applicable" items. The sum is then divided by the maximum possible score and multiplyed by 100 to yield a final score between 0 and 100. A score of 100 indicates no functional disability and 0 indicates the worst functional disability.
Time frame: From enrolment to two years postoperative
Toronto Extremity Salvage Score Upper Extremity
Sum of patient responses for each question on a 5-point Likert scale, excluding "not applicable" items. The sum is then divided by the maximum possible score and multiplyed by 100 to yield a final score between 0 and 100. A score of 100 indicates no functional disability and 0 indicates the worst functional disability.
Time frame: From enrolment to two years postoperative
Demographic Survey
Time frame: Enrolment
App Survey
Survey administered at the end of study participation to assess satisfaction and user-friendliness of the ACTIVATION app using Liekert scales. Survey also contains three short answer responses collecting feedback about the app and gathering data on technical difficulties. Last section of the survey contains questions about phone use habits using multiple choice questions..
Time frame: Single collection time point at 1 year post-operative.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — To protect participant privacy and confidentiality, the investigators will not share IPD with other researchers. The study involves sensitive or identifiable health information and the consent obtained from participants does not include permission to share their individual-level data publicly or with third parties.
Started Jul 2025 (actual). Primary completion is estimated for Jun 2030, 59 months after the start.
Of 88 non-industry observational studies under Sarcoma, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 294. This study's planned 59 months is below that.
Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 42 and three quarters within 294.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.